IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2

Aim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics.

Materials and methods. 108 patients suffering from HP-associated gastric ulcer disease were randomly divided into two groups. The I group of patients was cured with standard three or four component methods of therapy included proton pomp inhibitors and two antibiotics (usually Klaritromycin and Amoxicillin). Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 – Roncoleukin into four – six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously. This procedure was performed three times with the interval of 72 hours.

Results. One month after the end of treatment it was found that in the group treated with rIL-2 the HP eradication achieved in 95,4% in comparison to 81,5% in control patients. In Roncoleukin treated group ulcer epithelization period was 10,79±0,46 days and in traditionally treated group – 35,23±1,58 days. In third month of monitoring in gastric mucosae bioptates of basic group patients in 93,5% there were no morphological inflammatory signs and in 81,4% of patients intestinal metaplasia disappiered. Conclusion. The proposed method of complex treatment of gastric ulcer associated with Helicobacter pylori is clinically and pathogenetically justified. 

1. Baransraya E.K. Yazvennaya bolezn i infektsiya Helicobacter pylori //Russkiy meditsinskiy jurnal. – BOP. – 2000. – №1. – S.8-14.

2. Aruin L.I., Kapuller L.L., Isakov V.A. Morfologitceskaya diagnostika bolezney jeludka i kishetcnika. – M.: Triada-X, 1998. – 362 s.

3. Ivashkin V.T., Lapina T.L. Gastroenterologia XXI veka // Russkiy meditsinskiy jurnal. – 2000 – Т.8, №17. – S. 697-703.

4. Sheptulin A.A., Mardanova O.A. Obsujdenie problemi infektsii Helicobacter pylori v hode Evropeyskoy gastroenterologitceskoy nedeli // Ross. Jurn. gastroenter. gepatol. koloproktol. – 2004. – Т.14, №2. – S.88-92.

5. Lapina T.L. Farmakoterapiya erozivno-yazvennih porageniy geludka i dvenadtcatiperstnoy kishki //Russkiy meditsinskiy jurnal. – BOP. – 2003. – Т.5, №2. – S. 86-90.

6. Tcimmerman Y.S. Gastroduodenalnaya patologiya i Helicobacter pylori: totcka zreniya // Klin. farmakol. i ter. – 1999. – №2. – S. 37-40.

7. Montague S., Buckley M., O’Morain K. Treatment of Helicobacter pylori // Current Opinion in Gastroenterology. – 1999. – Vоl.15. – Suppl 1. – P. 35-42.

8. Moran A.P. The role of lipopolysacchande in Helicobacter pylory pathogenesis // Aliment Phatmacol Ther. – 1996. – Vоl.10. – Suppl 1. – Р.57-64.

9. Sharobaro V.I., Bogatcev R.S., Solovjov A.S. Opredelenie subpopulyatcionnogo sostava kletok immunnoy sistemi bolnyh jazvoy dvenadtcatiperstnoy kishki // Ross. Jurn. gastroenter. gepatol. Koloproktol. – 1999. – Т.9, № 6. – S. 49-52.

10. Soares T. F., Queiroz D. M. M., Rocha G. A., Rocha A. M. C., Cinque S. M. S., Carvalho A. S. T., Bittencourt P., Nogueira A. M. F., Oliveira C. A., Mendes C. M. C., Correa-Oliveira R., Martins-Filho O. A., Moreira E. F. Immunophenotype analysis of mononuclear cells (MNC) of Helicobacter pylori (HP) positive and negative children and adults // Current Opinion in Gastroenterology. – 2001. – Vol. 17. – Suppl 1. – P. 84.

11. Klinitceskaya immunologiya. (Pod red. A.V. Karaulova). – M.: Meditcinskoe iformatcionnoe agenstvo, 1999. – S. 306-307.

12. Dey A., Yokota K., Kobayashi K., Oguma K., Hirai Y., Akagi T. Antibody and cytokine responses in Helicobacter pylori-infected various mouse strains // Acta-Med-Okayama. – 1998 Feb. – Vоl.52, №1. – Р. 41-48.

13. Ihan A., Tepez B., Gubina M., Malovrh T., Kopitar A. Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients // Hepatogastroenterology. – 1999. – Vоl. 46, №27. – P. 1740-1745.

14. Mitchell H. M., Wiseman M., Ally R., Ahmed R., Segal I. The cytokine response to H. pylori is significantly different in symptomatic Sowetans compared with symptomatic Australians // Current Opinion in Gastroenterology. – 2001. – Vol. 17. – Suppl 1. – P. 17.

15. NazarovV.E. Primenenie Ronkoleykina v letcenii jazvennoy bolezni lukovitci dvenadtcatiperstnoy kishki // Materiali konferentcii: “ Ronkoleykin – novie aspekti klinitceskogo primeneniya”. – SPb.: MAPO. – S.-Peterburg, 1999. – S. 24-27.

16. Isakov V.A., Domaradskiy I. V. Shelikobakterioz. – M.: Medpraktika-M., 2003. – 411s.

17. Bamford K.B., Fan X., Crowe S.E., Leary J.F., Gourley W.K., Luthra G.K., Brooks E.G., Graham D.Y., Reyes V.E., Ernst P.B. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype // Gastroenterology. – 1998. – Vоl. 114, №3. – Р. 482-492.

18. Shkitin V.A., Shpirna A.I., Starovoytov G.N. Rol Helicobacter pylori v patologii tceloveka // Jurn. Klinicheskaya mikrobiologiya i antibakterialnaya terapiya. – 2002. – №3. – S. 11-40.

19. Zavros Y., Reider G., Ferguson A., et al. Hypergastrinemia in response to gastric inflammation suppresses somatostatin // Am J. Physiol Gastrointest Liver Physiol. – 2002. – Vоl. 282. – Р. 175-183.

20. Konagaya Т., Kusugami K., Nishio Y., et al. Negative correlation between somatostatin levels and interleukin-8 activity in gastric antral mucosa // Gut. – 1997. – Vоl. 41. – Suppl 1. – Р. 24.

21. Van den Brink G.R., ten Kate F.J., Ponsioen C.Y., Rive M.M., Tytgat G.N., van Deventer S.J., Peppelenbosch M.P. Expression and Activation of NF-B in the Antrum of the Human Stomach // J. Immunology. – 2000. – Vоl. 164. – Р. 3353-3359.

22. Кhanferyan R.A., Smirnova T.A., Ponomarjova E.P., Borovikov O.V., Du Buske L.M. Immunotherapy with Interleukin-2 of Helicobacter pillory-associated gastric ulcer disease // 2004. Annual Meeting American College of Allergy, Asthma & Immunology. November 12-17, 2004. – Boston. Abstract Book. – P. 73.